New T‑cell therapy targets three tumor proteins, shows early survival gains in aggressive pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National Hospital using a ...
MPR

Skyrizi Earns FDA Pediatric Approval for Psoriatic Disease in Patients Aged 6+

The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...
Medscape

FDA Extends Risankizumab Approval to Children With Psoriasis, Psoriatic Arthritis

The interleukin 23 inhibitor was approved for treating moderate-to-severe plaque psoriasis in adults in 2019 and for active ...